| Abstrakt: |
Researchers from the Dana-Farber Cancer Institute have published a new report on endometrial cancer. The study explores the combination of abemaciclib, letrozole, and LY3023414 in recurrent endometrial cancer. The research was terminated prematurely after five patients initiated protocol therapy due to the discontinuation of further development of LY3023414. The study includes findings from these patients, including one who achieved a partial response to letrozole/abemaciclib/LY3023414 after progressing through letrozole/everolimus. [Extracted from the article] |
